Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07345845 · ClinicalTrials.gov registry record · Early Phase 1
MR and Inflammation After Preeclampsia
A Early Phase 1 study of Preeclampsia and Preeclampsia Postpartum, sponsored by Anna Stanhewicz, PhD.
- Active
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07345845 is a Early Phase 1 study of Preeclampsia and Preeclampsia Postpartum that is active but no longer recruiting, run by Anna Stanhewicz, PhD. The registered enrollment target is 40 participants, below the 1,281-participant average among 39 other Preeclampsia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07345845, a Early Phase 1 study of Preeclampsia and Preeclampsia Postpartum, is active but no longer recruiting, sponsored by Anna Stanhewicz, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this investigation is to examine the role of inappropriate mineralocorticoid receptor activation in endothelial dysfunction and vascular inflammation in otherwise healthy women with a history of preeclampsia. The main questions it aims to answer are: 1. Does overactivation of the mineralocorticoid receptor contribute to reduced endothelial function in women who had preeclampsia? 2. To what extent does the mineralocorticoid receptor mediated exaggerated production of inflammatory cytokines in immune cells from women who had preeclampsia? Participants will visit the research laboratory for 2 experimental visits: * Visit 1: Skin blood flow will be measured using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) to examine blood vessels in a nickel-sized area of the skin. * Visit 2: Endothelial cells will be collected from an antecubital vein.
Conditions Studied
Interventions
- DRUG Eplerenone
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2029-02-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07345845
The ClinicalTrials.gov registry entry for NCT07345845 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,281-participant average among 39 other Preeclampsia trials with a reported enrollment target (97% lower). The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Eplerenone is the first listed.
NCT07345845 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT07345845 about?
NCT07345845 is a clinical study titled "MR and Inflammation After Preeclampsia". The purpose of this investigation is to examine the role of inappropriate mineralocorticoid receptor activation in endothelial dysfunction and vascular inflammation in otherwise healthy women with a history of preeclampsia. The main questions it aims to answer are: 1. Does overactivation of the min...
What is the current status of trial NCT07345845?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2025-12-17. Estimated completion is 2029-02-01.
What conditions does trial NCT07345845 study?
This clinical trial studies the following conditions: Preeclampsia, Preeclampsia Postpartum.
What interventions are being tested in trial NCT07345845?
The interventions under investigation include: Eplerenone (DRUG).
Who is sponsoring clinical trial NCT07345845?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07345845 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Prenatal Aspirin and Postpartum Vascular Function
RECRUITING · Early Phase 1
-
Predictors of Aspirin Failure in Preeclampsia Prevention
RECRUITING · Early Phase 1
-
Vascular Effects of High-Salt After Preeclampsia
RECRUITING · Early Phase 1
-
Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)
COMPLETED · Early Phase 1
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.